Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Fallopian Tube Neoplasms 4 Ovarian Neoplasms 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Solitary Fibrous Tumor, Pleural 1 Small Cell Lung Carcinoma 1 Sarcoma, Alveolar Soft Part 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Melanoma 1 Leiomyosarcoma 1 Glioblastoma 1 Fallopian Tube Mucinous Adenocarcinoma 1 Colorectal Neoplasms 1 Carcinosarcoma 1 Carcinoma, Endometrioid 1

Interventions

Doxorubicin 6 Specimen Handling 5 Radiotherapy 3 Radiation 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Gemcitabine 3 Biopsy 3 pembrolizumab 2 liposomal doxorubicin 2 eribulin 2 Ifosfamide 2 toripalimab 1 talimogene laherparepvec 1 rucaparib 1 ribociclib 1 regorafenib 1 peposertib 1 pazopanib 1 olaratumab 1 olaparib 1 lenvatinib 1 futibatinib 1 durvalumab 1 dinutuximab 1 cemiplimab 1 cediranib 1 cabozantinib 1 avelumab 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Leiomyosarcoma × cediranib × 1 year × Clear all

NCT03851614 2026-02-09

DAPPER

University Health Network, Toronto

Phase 2 Active not recruiting

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡